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Abstract. Recent advances in the rational &sign of drug molecules based on a graph-theoretical 
approach are briefly reviewed. Graph theory has not been widely recognized to date as an effec- 
tive alternative to the empirical procedures currently prevailing in the development of new drugs. 
Moreover, the problems confronting researchers in this field are daunting in their great complexity. 
We advocate here a novel yet simple mathematical formalism which opens up a promising new 
avenue of research. After outlining the fundamental premises of our method, we exemplify it 
by discussing the characterization, comparison, and quantification of similarity among individual 
molecules. It is indicated how the essential bioactive component in molecules of compounds 
displaying similar pharmacological behavior may be identified. We conclude by describing the 
pharmacological classification of 18 compounds, all of which are structurally similar but which 
exhibit several differing types of bioactivity. 
Keywords. Drug design; graph theory; optimization techniques. 
INTRODUCTION 
The history of drug development abounds in examples 
of major discoveries being made either serendipitously 
or as a result of following totally erroneous procedures 
(Burger, 1983). In spite of this circumstance, however, 
it was recognized very early on that the bioactivity 
of drug molecules was dependent upon the presence 
of special structural features in such molecules. It 
was pointed out by Crum Brown and Fraser (18681, 
for instance, that the quaternary ammonium group 
was essential for the blocking activity of curare-type 
drugs. Exactly one hundred years ago, Paul Ehrlich 
(1885), the founder of modern medicinal chemistry, 
elucidated the role played by enzymes in living systems. 
He thereby simplified the problem of drug interaction 
from one involving the study of cellular complexity 
to one involving complexity at no more than the mole- 
cular level. Ehrlich’s work laid the foundation for 
our current theories of drug action, drug metabolism, 
and drug resistance. 
Unfortunately, even today, very little is known about 
the mechanism of drug action or the underlying dynamics. 
The principal reason for this lacuna is a lack of knowledge 
of the structure of the relevant enzymes and an absence 
of detailed descriptions of their active sites. By contrast, 
most drugs can be viewed as small molecules (with 
a few notable exceptions) and are thus much more 
accessible to study. The fundamental problem in 
bioactivity studies therefore resolves itself into one 
of investigating the interaction of a relatively small, 
well characterized molecule with an unknown large 
protein molecule. Clearly, this represents an exceedingly 
difficult problem given the current level of our know- 
ledge. Moreover, until our understanding of the partici- 
pating protein and enzyme molecules approaches that 
existing for small molecules, and until our knowledge 
of all the intermediate steps which occur in an organism 
after administration of the drug becomes very detailed, 
such difficulties are likely to remain with us. This 
observation necessarily implies that we are very far 
from a situation where the use of any kind of rigorous 
theoretical technique could be comtemplated. 
In coming to terms with the present state of affairs, 
pragmatism would seem to point in the direction of 
sacrificing our curiosity on how the whole process evolves 
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and focusing instead on what is now within our reach. 
If we adopt a typical systems analysis approach (White 
and Tauber, 19691, we may probe the system by means 
of an appropriate input (drug) and then examine the 
resultant output (pharmacological activity). 
Approximate schemes, empirical rules, statistical 
methods, and mathematical modelling might thus appear 
as the only reasonable routes to encompassing the 
vast amount of data on drugs which have accumu- 
lated over the years. The situation confronting us, 
however, is perhaps not as bleak as it may at first 
seem, for there is a good deal of evidence which 
indicates that apparently similar compounds exhibit 
closely similar pharmacological activities. 
One of the first to recognize the relationship between 
the structure and activity of drugs was Emil Fischer 
(1894) in a paper entitled “Influence of configuration 
on the action of enzymes.” The basic model that he 
put forward assumed that enzymes have recognition 
sites, i.e. receptor locations, that are highly specific 
structurally. Binding to a host, i.e. a drug, would be 
possible only if essential structural fragments in the 
drug molecule match up precisely with those at the 
receptor site. In more informal terms, this matching 
can be described in terms of a ‘lock and key’ analogy, 
with the drug playing the role of the key. The current 
status of medicinal chemistry can be summed up by 
stating that the available ‘keys’ are being employed 
to probe unknown ‘locks’ with a view to constructing 
improved ‘keys’ that will better fit the ‘locks’. 
In mathematical parlance, the above represents an 
example of a reconstruction problem: by collecting 
a fair number of responses, one tries to determine 
the optimal input. By inversion of its own connectivity, 
an optimal key molecule would certainly be able to 
provide valuable information about the structure of 
its receptor. In practice, once a reliable lead compound, 
i.e. a structure that triggers a useful response, has 
been identified, the next problem of selecting structures 
with enhanced biological activity would not be soluble 
without some guidelines as to the method of picking 
out the small number of highly active molecules from 
the usually enormous number of possible candidates. 
There is an astronomical number of combinatorial 
possibilities associated with even a modest number 
of substitution sites on a molecule and (say) a dozen 
or more potential substituents. Thus, starting from 
a given lead molecule, the essential task becomes 
one of devising some scheme whereby those few candi- 
date structures which can function even more effect- 
ively as drugs’ than the lead can be recognized. 
-l-HE FUNDAMENTAL POSTULATE 
Currently, two fundamentally different philosophies 
underlie the various approaches to the rational design 
of drugs. The first involves considering a large data 
set of compounds and reducing the size of the set 
by means of a number of empirical schemes, all of 
which are based essentially on statistical analysis. 
This reduces the problem to one of lower dimension 
and normally gives an indication of which parameters 
are critical. Once established, these parameters can 
be employed in the prediction of novel candidate drug 
molecules. Representative methods based on this 
school of thought include pattern recognition (Stuper 
et al., 1979) and regression analysis (Hansch, 1969). 
The second philosophy entails considering a small data 
set of compounds, the aim now being recognition of 
the degree of similarity between compounds of similar 
pharmacologic or therapeutic value. Exclusive use 
is made here of structural parameters for the description 
of the drug molecules, with the emphasis falling on 
the mathematical properties of the structures involved. 
Comparison of structures having similar mathematical 
properties is undertaken on the assumption that such 
structures will also display similar physical, chemical, 
and biological properties. 
The fundamental basis of the second school of thought 
may be expressed in terms of the following postulate 
(Randit 1985a): 
POSTULATE: Structures which display substantial 
similarity in their mattiematical properties will also 
display considerable simjlarity in their physical, 
chemical, and biological properties. 
This postulate has a number of very important impli- 
cations, each of which we now outline and assess in 
some detail: 
(i) The various natural properties of chemical species 
may be characterized in purely mathematical 
terms. This is wellknown to be the case, witness 
the widespread use of topological indices (Bonchev, 
1983) in the description of many natural phenom- 
ena. It was first suggested by Rouvray (1973) 
that topological indices might be used as mathe- 
matical descriptors for candidate molecules 
in drug design studies. The feasibility of this 
type of approach has been amply demonstrated 
in recent years (Kier and Hall, 1976); 
(ii) The natural properties of chemical species are 
merely reflect ions of inherent mathematical 
properties of the structures concerned. According 
to this view, chemical species characterized 
by similar mathematical descriptors will be 
(iii1 
(iv) 
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possessed of similar physical, chemical, and 
biological properties. This statement is equivalent 
to saying that, if the mathematical descriptors 
of two structures are closely similar, the structures 
concerned will behave as isoteres, i.e. molecules 
which have related physicochemical properties 
and which exhibit broadly similar bioactivity 
(Langmuir, 1919; Thornber, 1979). Such a 
formulation places the focus of interest on the 
mathematical properties of structures and 
indicates that the natural properties may be 
compared and predicted by assessing the 
mathematical features of the structures concerned; 
In going from structure to structure among mole- 
cules which are closely similar, it is postulated 
that there exist a rough continuum in the physical, 
chemical, and biological properties of the various 
species. Although it can never be strictly accurate 
to refer to a continuum when reference is made 
to discrete objects, i.e. molecules, it is our con- 
tention that very small changes in the neighborhood 
relations within the set of molecules will result 
in only minor changes in their natural properties. 
Thus, provided an appropriate set of structures 
is chosen, a more or less continuous range of 
properties can be generated without any significant 
gaps and with no abrupt changes; 
Based on the above statement, it follows that, 
by making a suitable selection of structures 
and their substituents, any &sired range of natural 
properties can be realized for a specific set 
of structures. In the light of the foregoing, the 
initial selection process would have to entail 
characterization of the mathematical nature 
of the candidate structures and the collection 
together of those structures which display only 
slight differences in terms of their mathematical 
descriptors. The use of mathematical criteria 
for the purpose of clustering structures around 
some defined natural property will form the 
subject matter of most of the rest of this presen- 
tation. 
Although our postulate serves as an effective paradigm 
in specifying how chemical structures may be clustered 
around some natural property of interest, it does not 
reveal how the mathematical characteristics will be 
manifested in terms of the various natural properties 
of the set of chemical compounds investigated. In 
this respect, it is quite unlike the axioms of quantum 
theory or the laws of classical physics. Moreover, 
it should be mentioned that the postulate does not 
necessarily apply to individual compounds which are 
regarded as forming a continuum. In appropriate 
contexts, the postulate can refer to composite systems 
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such as a drug-enzyme pair. A major criticism to 
our type of approach has been that chiral structures 
have the same mathematical properties (since they 
are identical in all respects apart from irrelevant 
mirror reflections) yet display dramatically different 
brological activities. Such criticism is invalid because 
the biological property under consideration in this 
situation is not that arising from a single, isolated 
structure but rather one from a drug-receptor pair. 
A valid comparison would study the mathematical 
properties of the drug-receptor pairs for both antipodal 
structures. This sort of comparison would reveal that 
the two systems were not alike at all and were in fact 
quite different. 
OUTLINE OF GRAPH-THEORETICAL SCHEMES 
In order to proceed with our treatment, it will be neces- 
sary to accomplish three tasks, viz (i) to represent 
all the structures of interest in mathematical terms, 
i.e. as chemical graphs; (ii) to prescribe some compar- 
ability test that will indicate how much two given 
structures differ; and (iii) to recognize the significant 
components in the molecules considered. The first 
two of these tasks have been addressed in many publi- 
cations discussing the graph-theoretical approach 
to structure-activity studies (RandiC and Wilkins, 1979a, 
1979b; Wilkins and Randie 1980; Wilkins et al., 1981; 
Randit 1985a; Jerman-Blazit et al., 1985), and thus 
need not be further elaborated here. For our purposes 
we shall represent chemical compounds by their mole- 
cular graphs with the nonessential hydrogen atoms 
suppressed in the customary fashion (Trinajstit 1983), 
though we shall also discuss the representation of 
structures by appropriately weighted path numbers. 
Our main focus of attention, however, will be on task 
(iii) and the means of identifying the essential compon- 
ents within a set of structurally related compounds 
displaying differing pharmacological activities. 
FIG. 1. Graph of the molecule of phenylethylamine. 
Let us first consider the compound shown in Figure 
1 and assign an arbitrary numbering to the atoms therein. 
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Drug Name 
Phartnacebgical 
Classification 
Therapeutic 
Applicaiien 
Q-cH+~I-HH~ __ Amphetamine 
CH, 
CNS Stimulant Antidepressant 
Anorexiant 
Narcolepsy . 
Minimal Brain 
Dysfunction 
OH CH, 
3. Q-w+;--NH--CH, 
CHs 
CH, 
6. CY-CH,-NH, 
HO OH 
7. CH- CH-NH, 
Ck dH , 
8. T-cHrNH-cH’ 
OH 
Phenylpropanoamine (1 -Agonist 
CNS Stimulant 
Methamphetamine CNS Stimulant 
Phentermine CNS Stimulant 
Hydroxyamphetamine a -Agonist 
Levarterenol 
Metaraminol 
cx -Agonist 
D -Agonist 
Methamphetamine CNS Stimulant 
Decongestant 
Anorexiant 
Anorexiant 
Antidepressant 
Narcolepsy 
Minimal Brain 
Dysfunction 
Anorexiant 
Antihypotensive 
Antihypctensive 
Vasoconstrictor 
Antihypotensive 
Anorexiant 
Minimal Brain 
Dysfunction 
Antidepressant 
Narcolepsy 
PIG. 2. Set of graphs of m~kcule~ closely related to the phenylethylami~ ml-le. 
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CH-CH-NH-CH, 
L C’H 3 
Ephedrine a-Agonist 
CNS Stimulant 
Antihypotensivt 
Decongestant 
Bronchodi later 
Antiarrhythmic 
CH, 
Mephentermine CNS Stimulant 
a-Agonist 
Antihypotensive 
11. 
HO 
CH-CHi_NH-CH, 
1 
OH 
Epinephrine a-Agonist 
B-Agonist 
Antihypotensive 
Bronchodilator 
Decongestant 
Antiarrhythmic 
12. Bronchodilator Methoxyphenamine B-Agonist 
HO 
Ethylnorepinephrine B-Agonist Bronchodi later 
otl 
Lo 
14. 
CH,--H-NH, 
HO 
Antiparkinsonian Levodopa CNS Agent 
15. 
HO 
OH 
c=o Methyldopa CNS Agent 
16. Methoxamine (1 -Agonist 
Antihypertensive 
Antiarrhythmic 
Antihypotensive 
CH, 
17. H 
O-P- 
/ 
0 C;-CH,-NH-CH 
OH \H, 
HO 
18. 
6 -Agonist Antiarrhythmic 
Bronchodi lator 
lsoproterenol 
Diethylpropion CNS Stimulant Anorexiant 
FIG. 2. Set of graphs of molecules closely related to the phenylethylamine molecule. (continued) 
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This particular compound is closely related to all of 
the compounds depicted in Figure 2. The simplified 
molecular graphs we are using here do not differentiate 
between aromatic and aliphatic C-C bonds, and-neither 
do they distinguish between single C-C and C-N bonds. 
Our ultimate interest concerns the set of compounds 
shown in Figure 2, all of which possess certain identical 
structural features: a phenyl ring and a nitrogen atom 
removed from the ring by three bonds. In the present 
context, differentiation between bond types turns out 
to be of no great consequence; in fact it was recently 
demonstrated (Grossman et al., 1985) that character- 
ization of structures by means of weighted paths (where 
heteroatoms were given differing weights) was rather 
insensitive to the actual choice of weights. 
Our characterization of the compounds illustrated above 
will be based on the counts of paths of different lengths. 
A path of length k will represent a fragment containing 
k consecutive bonds, i.e. a chain of length k. By conven- 
tion, paths of length zero represent atoms, paths of 
length one count the number of bonds, paths of length 
two count the number of pairs of consecutive bonds, 
and so on. In Table 1 we present the counts for paths 
of increasing length for each of the atoms in the com- 
pound depicted in Figure 1. These counts were arrived 
at by making use of the ALLPATH program (Randie 
et al., 19791. For compounds having no more than a 
single ring and a few atoms, carrying out the counts 
is not particularly onerous, yet, even for bicyclic systems, 
it becomes impractical to perform the counts by hand. 
The last row in Table 1, having the entries 9 9 10 11 
12 12 6 4 2, gives the path counts for the molecule 
as a whole. These counts can be readily derived from 
the data on the individual atoms if it is remembered 
that all the paths (except those of zero length) have 
been counted twice -- once for each end atom. The 
molecule in Figure 1 thus has 9 atoms, 9 bonds, IO adja- 
cent pair bonds, 11 sets of three consecutive bonds, 
and so on. 
The advantage of using path numbers, as opposed to 
molecular fragments, such as bonds or small atomic 
groups, is that the path numbers retain some information 
on the nonlocal connectivity within the structure. How- 
ever, it is evident that the number of paths of inter- 
mediate length dominate in the path counts, a fact 
which may result in similarities among compounds due 
to local characteristics being obscured. From studies 
on isomeric variations in the physicochemical properties 
of species (RandiCand Wilkins, 1979c, 1979d; Randic 
and Wilkins, 1980; Randicand Trinajstit 1982). it has 
been established that shorter paths, especially those 
of lengths two and three, play a crucial role. It would 
thus appear desirable to introduce weighting of the 
TABIFl. ThegdputoftheAlIPATH 
0 1 
1 0 
0 1 
0 0 
0 0 
1 0 
0 0 
0 0 
0 0 
-____ 
1 
1 2 
-____ 
2 
1 2 
----_ 
3 
0 
1 
0 
1 
0 
0 
0 
0 
0 
3 
2 
1 2 2 
___-- 
4 
1 2 2 
_____ 
5 
1 2 3 
---__ 
6 
1 3 3 
----- 
7 
1 2 3 
_____ 
0 
1 2 1 
----- 
9 
1 1 1 
0 
0 
1 
0 
1 
0 
0 
0 
0 
3 
3 
2 
3 
3 
3 
2 
2 
1 
----__---_ 
9 9 10 11 
0 1 
0 0 
0 0 
1 0 
0 1 
1 0 
0 1 
0 0 
0 0 
3 2 
3 4 
4 4 
3 4 
3 2 
2 2 
I 
2 2 
2 2 
2 2 
12 12 
1 
1 
2 
1 
1 
0 
2 
2 
2 
6 
TOTAL NUMBER OF PATHS: 75 
paths in order that the dominant role of the more 
abundant paths of intermediate length can be 
counteracted, and the role of the shorter paths given 
greater prominence. As weighting of paths based 
on a differentiation of bond types has been found 
effective for such purposes (Menon and Cammarata, 
1977, Randie 1984a; Randit 1985a), we shall adopt 
this approach here. 
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To carry out the weighting, each bond is classified as 
being of (m,n) type, where m and n are the numbers 
of edges emanating from each of the terminal vertices 
of the bond in question. For all bond types cm,&, a 
weight of (m x n)-f is assigned to each bond, following 
the same procedure adopted in computing the connectivity 
indices of molecules (Rand& 1975). This weighting 
procedure many be used in conjunction with the widely 
available ALLPATH program (Randi& et al., 1980) 
provided the weights are entered as input. Alternatively, 
a subroutine may be added to the existing program 
to automatically introduce weightings in the counting 
process (Randit 198513). In Table 2 are listed the counts 
for the weighted paths of the compound depicted in 
Figure 1. The results represent the printed output of 
a modified ALLPATH program. 
In addition to the path numbers, i.e. the numbers of 
paths of different length, the output also gives for each 
atom the total of all the paths pertaining to that atom. 
Thus, for atom 1 this total is 3.011 whereas for atom 
2 it is only 2.989, and so on. It appears that these ‘atomic’ 
numbers are able to differentiate between atomic 
environments; they may therefore be referred to as 
atomic identification (ID) numbers. The last line of 
the output, reproduced here with the numbers truncated 
to three decimal places: 
9 4.431 2.215 1.098 0.574 0.276 0.071 
0.025 0.007 
represents the (weighted) path counts for the molecule 
as a whole. The total number of paths, 17.7005, has 
been termed the molecular ID (identification number), 
and has been shown to be a highly discriminating (Randit 
1984a) though not unique (Szymanski et al., 1985) index. 
COMPARISON OF DIFFERENT STRUCTURES 
For the molecule illustrated in Figure 1, Table 2 provides 
a set of graph invarrants that may be used in comparing 
similar data on a variety of other structures. A sequence, 
such as the above list of paths of different lengths, 
or a set of numbers, such as the list of all ‘atomic’ 
numbers, clearly offers a broader basis for the comparison 
of structures than (say) a single topological index, such 
as the connectivity index originally introduced to discuss 
the branching in alkane molecules and variations among 
the physicochemical properties of isomeric species 
(Rand& 1975). As will be evident, even the use of 
a single number as a descriptor, e.g. a partial sum of 
selected ‘atomic’ numbers, can yield extremely useful 
information from the comparisons between structures. 
To those not especially well versed in chemical graph 
theory, it may come as something of a surprise that 
a single number is able to capture so much of the 
essential structural information associated with chemical 
species, though this observation has been amply 
corroborated in the manifold applications of the 
connectivity index. Such numbers, which to the 
uninitiated may appear to be ad hoc in origin, are 
in fact based upon well-defined and important structural 
invariants. 
The information presented in Table 2 can be used in 
several different ways. The path numbers for each 
compound may be viewed as the components of a vector 
and the degree of similarity existing between different 
vectors then established. The similarity can be defined 
in terms of the Euclidean distance between the position 
vectors in n-dimensional space. This general type 
of analysis has already been applied to the dopamines, 
benzomorphans, barbiturates, and aminotetralins (RandiC 
and Wilkins, 1979c; Randicand Wilkins, 1979d; Randit 
and Wilkins, 1980; Randitand Trinajstil 1982). Alterna- 
tively, structures may be represented by sets comprised 
of the relevant atomic path sums, where the summation 
is restricted to selected atoms only, as illustrated 
in the search for optimal antitumor drugs (Randi 
1985a). Use of the molecular ID numbers for the purpose 
of clustering compounds together can be made only 
on the basis of similarities existing among the individual 
ID values. In the cases of several therapeutically 
valuable antihistamines, anticholinergics, antipsychotics, 
antidepressants, analgesics, and antiparkinsonians, 
however, surprisingly good classifications based solely 
on this single structural parameter have been obtained 
(Randit, 1984133. 
As will be evident from Table 2, ID numbers are size- 
dependent. For the compounds we have considered 
here, each atom contributes around 2.25 to 3.00 to 
the ID number. It seems quite likely that such ‘size’ 
effects may obscure some of the finer structural differ- 
ences existing among the compounds illustrated in 
Figure 2. The effect may be especially pronoucned 
here because all the molecules concerned are relatively 
small, i.e. they contain no more than lo-15 atoms 
each, not counting the suppressed hydrogen atoms. 
In the following section, we shall select a fragment 
present in all the compounds of Figure 2. Comparison 
of the compounds will be based solely upon the 
characteristics of the atoms common to all the 
structures considered. 
CLUSTERING OF THE THERAPEUTICALLY 
RELATED SPECIES 
The compounds represented in Figure 2, all of which 
are therapeutically very efficacious, form a subset 
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_ - - _ _ .- 
1 .908248291 .S83333333 .291666667 .163092232 
.0463488515 .0104166667 5.20833334E-03 3.68284782E-03 
3.01199722 
2 
1 
.0919627826 
2.98990033 
1 
.0104166667 
.454124145 .291666667 
0 
.I3436437 
7.36569564E-03 
3 
1 .5 .204124145 
.0294627826 0 0 
.166666667 
-0833333334 
2.98358693 
---__ 
4 
1 .454124145 .291666667 .13436437 
.0104166667 7.36569564E-03 0 .0919627826 
2.98990033 
__--- 
5 
.908248291 .583333333 .291666667 .163092232 
.0104166667 5.20833334E-03 3.68284782E-03 .0463488515 
3.01199722 
-____ 
6 
1 
.0510310363 
3.33867213 
_---- 
7 
1 
.0416666667 
2.90763502 
_---_ 
8 
1.22474487 .612372436 .348461713 .102062073 
0 0 0 
.908248291 .686886724 .166666667 
.0208333333 0 0 
.0833333334 
1.20710678 .204124145 . 1666666667 .0833333334 
.02083333333 .0104166667 0 .0416666667 
2.73414759 
___-_ 
9 
1 
.0589255651 
2.43333431 
___-___--_ 
9 
.276623268 
.707106781 .353553391 .144337567 .11785113 
.0294627826 .0147313913 7.36569564E-03 
4.43185165 2.21592583 1.09846171 .57407987 
.0711294493 .025148058 7.36569564E-03 
TOTAL NUMBER OF PATHS: 17.7005855 
Drug 
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TABLE 3. The atomic ID number for the nine atoms common to all 18 structures of Fig. 2. 
1 
Atom positions: 
1 3.016 2.992 2.985 2.992 3.016 3.349 2.933 2.993 2.394 
2 3.015 2.992 2.985 2.992 3.015 3.347 3.156 2.967 2.379 
3 3.025 2.997 2.989 2.997 3.025 3.369 2.982 3.112 2.693 
4 3.017 2.993 2.9986 2.993 3.017 3.351 2.937 3.226 2.363 
5 3.016 2.980 3.198 2.980 3.016 3.357 2.936 2.994 2.395 
6 3.001 3.192 3.185 2.977 3.013 3.349 3.138 2.703 2.411 
7 3.004 3.203 2.971 2.990 3.018 3.352 3.158 2.967 2.380 
8 3.010 3.206 2.973 2.993 3.024 3.365 3.196 2.849 2.705 
9 3.201 2.995 2.988 2.995 3.021 3.360 3.196 3.086 2.682 
10 3.023 2.996 2.989 2.996 3.023 3.366 2.974 3.329 2.670 
11 3.009 3.196 3.188 2.981 3.022 3.369 3.197 2.850 2.705 
I2 3.350 3.028 3.013 3.019 3.049 3.408 2.998 3.119 2.696 
13 3.009 3.196 3.188 2.981 3.022 3.370 3.199 3.088 2.449 
14 3.009 3.196 3.188 2.981 3.021 3.369 2.962 3.054 2.430 
15 3.008 3.196 3.188 2.981 3.021 3.368 2.960 3.279 2.389 
16 3.362 3.045 3.040 3.341 3.074 3.410 3.177 2.974 2.383 
17 3.014 3.198 3.190 2.984 3.027 3.381 3.233 2.936 2.877 
18 2.983 2.973 2.970 2.973 2.983 3.272 3.138 3.083 3.155 
2 3 4 
of a collection of compounds investigated by Menon 
and Cammarata (1977) using pattern recognition tech- 
niques. From their collection of almost 40 compounds, 
we have selected 18 compounds whose molecules contain 
no cycles other than a single phenyl group, no chlorine 
atoms as substituents, and no quarternary nitrogen 
atoms. All of the selected compounds are closely related 
structurally: apart from having a phenyl ring, they 
all have a nitrogen atom three bonds removed from 
this ring. They do differ, however, in the number, type, 
and position of the various substituents they contain, 
namely the hydroxyl group, the methyl or ethyl groups, 
and occasionally the carbonyl group. In Table 3 a partial 
path characterization of these compounds is presented, 
with only the atomic path numbers appearing for the 
nine atoms common to all of the compounds. Inspection 
of Figure 2 reveals that the structure we have depicted 
in Figure 1 is the largest fragment common to all the 
18 compounds. 
The partial sums of the atomic path numbers for the 
nine common atoms are reported in Table 4. The nine 
atoms have now been partitioned into two groups: the 
six atoms constituting the phenyl ring are considered 
separately (for reasons which will become apparent 
later). The remaining entries in Table 4 are for the 
three atoms forming the side chain (including the 
nitrogen); the totals for the nine-atom fragment are 
also given in each case. These latter totals we shall 
refer to as the fragment ID numbers. Analysis of the 
5 6 7 8 9 
fragmentID numbers indicates that the ‘size’ effect 
mentioned above has now been eliminated. Use of 
the fragment IDS to order the compounds, however, 
leads to the disappointing result that such ordering 
produces no significant pharmacological classification 
of the compounds. 
(al 
(b) 
Q---- N 
I 
c N 
FIG. 3. The fragments thought to be essential for 
the activity of (a) the morphins, 8) -oleptics. 
(13 mutagenic nitroar-. 
The nine-atom fraament is comoarable in size with 
a number of other grouoinas identified as performing 
an essential pharmacophoric role in various drug 
580 5th ICnn 
TABLE 4. Partial sums of atomic path numbers 
for the ring and other atoms in the fragment kee Fig. 1). 
Drug Ring ID Side Frag- 
Chain ment 
ID ID 
Amphetamine 
Pheny I propano I amine 
Metamphetamine 
Phentermine 
Hydroxyamphetamine 
Levartereno I 
Metaraminol 
Pheny lephrine 
Ephedrine 
10 Mephentermine 
11 Epinephrine 
12 Methoxyphenamine 
13 Ethy lnorepinephrine 
14 Levodopa 
15 Methyidopa 
16 Metoxamine 
17 lsoprotereno I 
18 Diethylpropion 
18.353 8.321 26.675 
18.347 8.503 26.850 
18.404 a.788 27.193 
la.357 8.527 26.880 
18.548 8.326 26.875 
la.719 a.253 26.973 
18.541‘ 8.506 27.047 
la.573 a.751 27.324 
18.382 8.965 27.347 
18.396 8.975 27.371 
la.767 8.753 27.521 
18.870 8.814 27.685 
18.768 8.736 27.505 
18.766 8.446 27.213 
18.764 8.629 27.393 
19.274 8.535 27.809 
18.769 9.047 27.843 
la.155 9.376 27.532 
molecules. For instance, the empirical ‘morphine rule’ 
fragment (Lednicer and Mitscher, 1977), the fundamental 
structure proposed for neuroleptic action (Janssen, 
1964), and the significant fragment in the mutagenic 
nitroarenes (Klopman and Rosenkranz, 1984) are all 
of a similar size and each is claimed to be specific. 
The three fragments are illustrated in Figure 3. In 
our case, the nine-atom group we consider is clearly 
pharmacologically active, though its action is nonspecific. 
What is required at this point is a finer differentiation 
among the 18 compounds under consideration. 
In Figure 4 a histogram is presented based only upon 
the ring ID values, i.e. the values of the atomic path 
sums for the six atoms constitutmg the phenly ring 
in the 18 compounds of interest. Rather surprisingly, 
there is now a very evident clustering of all the central 
nervous system (CNS) simulants (which have lower values 
of the ring ID), and similar clusterings for the 8-agonists 
and the CNS agents. The latter group,which clusters 
in the central region of Figure 4, has too few compounds 
within it to give any great statistical significance 
to this particular finding. Moreover, by contrast, 
there is a wide scatter for the a-agonists over the 
whole range of ring ID values. 
These observations, which are highly interesting, might 
have escaped attention altogether if only a visual 
inspection of the structures had been made. Clustering 
19. 
19. 
_ 6-Agonist (12) 
18. B-Agonist (17) 
_ .-Agonist (II) B-Agonist (11) 
B-Agonist (13) 
_ a-Agonist (6) 
18. 
u-Agonist (8) 
= a-Agonist (5) 
- a-Agonist (7) 
ia. 
= a-Agonist (9) 
- a-Agonist (2) 
CNS stimulant (3) 
CNS stimulant (IO) 
CNS stimulant (9) 
CNS stimulant (4) 
CNS stimulant (I) 
CNS stimulant (2) 
18. 
FIG. 4. Classification of the bicactivity of the 
18 compounds considered based on their ring ID numbers. 
of all the CNS stimulants within the range of ring ID 
values lying between 18.35 - 18.40, which represents 
a small interval compared to the full range of possible 
ring ID values (from around 18.00 to 19.25) for the 
compounds under study, indicates that rings lying within 
this narrow range contain a specific structural cum- 
ponent essential for that particular type of pharmaco- 
logic activity. This interval relates, of course, only 
to unsubstituted phenyl rings, and careful inspection 
of the molecular diagrams might have revealed that 
such rings are essential for CNS stimulants. In the 
case of the E-agonists, a phenyl ring with two substit- 
uent hydroxyl groups appears to be essential, and the 
_ a-Agonist (16) 
CNS agent (15) 
CNS agent (14) 
CNS stimulant (18) 
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same seems to apply in the CNS agents. These can 
certainly be interpreted as positive results, although 
the scatter of the a-agonist ring ID values over the 
whole range of possible values must be seen as a negative 
result. The finding that for a-agonistic-type activity 
substitution (by hydroxyl groups) of the phenyl ring 
may occur is without special significance. 
CONCLUDING REMARKS 
In this presentation only one particular aspect of the 
graph-theoretical approach to quantitative structure- 
activity relationships has been examined. After visually 
identifying a common nine-atom fragment among a 
group of therapeutically valuable drugs, attention was 
focused on one critical component of the fragment. 
This component was a ring which played a major role 
in discriminating between structures for pharmacological 
classification purposes. Thus, it is important to recognize 
that not only fragments may be responsible for pharmaco- 
logical action, but that such fragments may need to 
be further subdivided in order to obtain a good correlation 
between a given structure and its function. Even a 
negative result, such as the discovery that the behavior 
of a fragment is insensitive to selective substitution, 
is of considerable interest in drug design studies. For 
one thing it suggests that the least expensive derivative 
may be used for any substitution which is irrelevant, 
provided that other factors, such as toxicity and dosage, 
remain unchanged. 
If the compounds listed in Figure 2 are. regarded as 
lead compounds, the analysis presented here can serve 
to indicate both productive and unfruitful approaches 
to the design of enhanced drugs. In the case of CNS 
stimulants, for instance, it is clear that it would be 
undesirable to attempt to substitute the phenyl ring, 
whereas for a-agonists this would be an allowed possi- 
bility. The actual direction adopted will, of course, 
depend very heavily on which particular standards are 
recommended as optimal. Compounds which appear 
most promising would in general differ least in the 
essential fragment, that is to say the mathematical 
characterization of the fragments should differ least 
from that of the lead molecule. Although it is not 
unreasonable to adopt the approach pursued in several 
similar studies reported previously (Menon and 
Cammarata, 1977; Trinajstit, 1983; Randie, 1985a), 
one has now gained important additional insights. It 
is much better known which part of the overall molecular 
characterization is most crucial. By clustering together 
structures that are most similar in their more significant 
str!;ctural details, some uncertainties in the search 
for dptimal drugs can certainly be eliminated. 
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